Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Pharmacogenet Genomics. 2009 Mar;19(3):235. doi: 10.1097/FPC.0b013e328320a3e2

Figure 1.

Figure 1

Percent of treatment outcome phenotypes of all subjects and Hispanic subset. Subjects who completed at least 6 wk of treatment with citalopram were assigned a remission phenotype based on the QIDS-C16 score at the last treatment visit. Broad phenotypic definition (BR) of treatment outcome grouped probable remitters under remitters and probable non-remitters with non-remitters